Bionano Genomics, Inc. has made a significant breakthrough in the analysis of multiple myeloma (MM) through the publication of a study in the American Journal of Hematology. This multicenter research, led by experts from Johns Hopkins University and The University of Texas MD Anderson Cancer Center, demonstrates that optical genome mapping (OGM) outperforms traditional cytogenetic methods in detecting structural variations and chromosomal abnormalities in MM, a notoriously challenging hematologic malignancy.

The study analyzed the largest cohort of MM samples to date, comprising 211 cases, and revealed that OGM achieved a higher overall success rate for identifying pathogenic abnormalities compared to conventional techniques like karyotyping, fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS). Notably, OGM successfully identified relevant chromosomal abnormalities in 92% of cases previously deemed normal by karyotyping and uncovered additional pathogenic findings in approximately 30% of subjects, showcasing its potential to provide a more comprehensive genomic profile. This advancement aligns with recommendations from medical societies for more thorough genomic profiling in MM.

For professionals in the longevity and healthspan research fields, the implications of this study are profound. The enhanced sensitivity and success rates of OGM could lead to more accurate diagnoses and better-informed therapeutic strategies for patients with MM. As the field moves toward more personalized medicine approaches, integrating OGM into standard laboratory workflows may not only improve patient outcomes but also drive broader adoption of advanced genomic technologies in oncology.

Source: globenewswire.com